item management s discussion and analysis of financial condition and results of operations general the following discussion and analysis should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this report 
the following table sets forth  for all periods indicated  the percentage relationship that items in the company s statements of operations bear to net sales 
year ended april  net sales cost of sales gross profit selling  general administrative expense research development costs contract research income interest expense interest income and other total expenses income before tax provision income tax provision net income results of operations for years ended april  and for the fiscal year ended april  fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the successful introduction of five new generic products into the marketplace and increased shipments to the company s existing customers 
the company s high level of customer service and the ability to produce high quality products have also contributed to our results 
the company s five leading products in fiscal were urea cream and lotion  sulfamethoxazole and trimethoprim  promethazine with codeine and promethazine dm  albuterol sulfate inhalation solution and syrup  and lactulose solution 
sales of urea cream and lotion accounted for of sales while sales of sulfamethoxazole and trimethoprim accounted for of sales for fiscal generic pharmaceutical products  which include private label contract manufacturing  had net sales for fiscal of  an increase of  or  compared to  in fiscal the increase resulted from increased demand and the successful introduction of five new generic products into the marketplace in fiscal which helped offset a significant decrease in sales of tannate based products 
sales were particularly strong for urea cream and lotion which recorded net sales of approximately  in its first year 

table of contents the company s tannate based products experienced lower sales as market demand shifted towards a new formulation  tussi d s marketed by medpointe 
the company was not able to ship its version of tussi d s because of a suit brought against it by medpointe  which resulted in a temporary restraining order against the company 
the company has filed an appeal of this ruling 
health care products division  which markets the company s branded products  had net sales of  and  for fiscal and  respectively 
net sales decreased by  or 
this decrease is primarily the result of exported health care products which were improperly returned to the domestic market during the first half of the year 
the company has taken the necessary steps to minimize the impact of this diversion and believes that its consequences are limited 
cost of sales  as a percentage of net sales  decreased from for fiscal to for fiscal the decrease in cost of sales as a percentage of sales was primarily driven by sales of certain new products  which have a higher gross margin than the average product in our portfolio 
in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as market conditions change 
selling  general and administrative expenses  as a percentage of net sales  increased from to  an increase of  the increase from  for fiscal to  for fiscal resulted principally from increased sales commissions  freight expenditures  and professional fees related to patents and legal defenses 
the company incurred a non cash pre tax charge for options granted in and to a consultant who is a director of the company in the amount of  for fiscal compared to  in fiscal this pre tax charge was based  in part  on the market value of the company s stock  which appreciated over the respective reporting periods 
research and development costs increased to  or for fiscal from  for fiscal as a result of  among other things  expenses associated with the filing of andas with the fda as well as development of non anda products for the company 
expenses increased due to significant costs associated with developing a steroidal nasal spray which requires both bioequivalency studies and clinical studies 
expenses associated with developing steroidal nasal sprays will continue into fiscal year additionally  the number of projects in development increased from to net income increased or  to  for fiscal from net income of  for fiscal  due to increased sales and gross margins  partially offset by higher research and development and selling  general  and administrative expenditures 
diluted earnings per share for fiscal were  unchanged from for the prior year due to the factors mentioned above and increased shares outstanding  due to  shares issued in a private placement and the exercise of outstanding options 
results of operations for years ended april  and for the fiscal year ended april  fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the successful introduction of new generic products into the marketplace in fiscal and increased shipments to the company s existing customers as well as several new customers in fiscal the company s high levels of customer service and the ability to produce high quality products has also contributed to our results 
some of the leading products that were included in this mix for the past year were albuterol sulfate inhalation solution and syrup  
table of contents sulfamethoxazole and trimethoprim  lactulose solution  promethazine dm  as well as promethazine with codeine  lidocaine and several other prescription products 
no one product accounted for sales of or more of total sales 
generic pharmaceutical products  which include private label contract manufacturing  had net sales for fiscal of  an increase of  or  compared to the fiscal the increase resulted from increased demand and the successful introduction of new generic products into the marketplace in fiscal health care products division  which markets the company s branded products  for fiscal and had net sales of  and  respectively 
net sales increased by  or 
cost of sales  as a percentage of net sales  decreased from for fiscal to for fiscal labor and overhead decreased approximately 
units shipped increased and the average unit selling price increased 
in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as market conditions change 
if one or more other generic pharmaceutical manufacturers significantly reduce their prices in an effort to gain market share or the supplier of active ingredients increases its prices  the company s profitability could be adversely affected 
selling  general and administrative expenses  as percentage of its sales  increased from to  an increase of  the increase from  for fiscal to  for fiscal resulted principally from increased sales commissions  freight expenditures  and professional fees 
the company incurred a non cash pre tax charge for options granted in and to a consultant who is a director of the company in the amount of  for fiscal this pre tax charge was based  in part  on the market value of the company s stock  which appreciated substantially over the respective reporting periods 
research and development costs increased to  or for fiscal from  for fiscal as a result of  among other things  expenses associated with the filing of abbreviated new drug applications andas with the fda as well as development of non anda products for the company 
net income increased or  to  for fiscal from net income of  for fiscal  as a result of the factors noted above 
liquidity and capital resources the company s operations are historically financed principally by cash flow from operations 
at april  and april   working capital was approximately  and  respectively 
the increase of  was primarily due to the private placement of  shares of common stock in july with net proceeds of  and cash flow from operations 
cash flows from operating activities were approximately  which was the result principally of net income and depreciation of  partially offset by an increase in accounts receivable of  the increase in accounts receivable is due to slower payments from customers 
the company has taken measures to add staff and increase collection efforts to manage the increase in accounts receivable 
the company expects to continue increasing expenditures in research and development in the future 
cash flows used in investing activities were approximately  and were principally payments for fixed assets acquired and investments in marketable securities 
cash flows from financing activities were  and resulted principally from the private placement of  shares of common stock in july with net proceeds of  and  from the net proceeds exercise of incentive stock options 

table of contents on october  the company replaced its existing credit facility with a new three year  revolving credit facility 
the revolving credit facility bears interest at a rate elected by the company equal to the prime rate or the libor plus 
loans are collateralized by inventory  accounts receivable and other assets 
the agreement contains covenants with respect to working capital  net worth and certain ratios  as well as other covenants and prohibits the payment of cash dividends 
at april  there were no borrowings under the credit facility 
on july  the company entered into a definitive agreement with certain accredited investors with respect to the private placement of  shares of its common stock at a purchase price of per share  for net proceeds after offering costs  of approximately million 
the net proceeds will be used mainly for the funding of future acquisitions  research and development and for general corporate purposes 
in june  the company acquired exclusive rights to market and distribute naprelan naproxen sodium controlled release tablets in the united states  its territories  and puerto rico 
elan pharmaceuticals  inc had provided the underlying rights to stat trade  inc sti and sti simultaneously assigned its rights to the license to hi tech 
as consideration for the acquisition  hi tech paid million in cash for the license  inventory and related acquisition costs 
hi tech will pay sti consulting fees on an ongoing basis based on net profits on the sales generated by naprelan 
the company believes that its financial resources consisting of current working capital  anticipated future operating revenue and its credit line will be sufficient to enable it to meet its working capital requirements for at least the next months 
in may  the company announced a stock buy back program under which the board of directors authorized the purchase of up to  of its common stock 
in november  the company increased the stock buy back program to an aggregate of  as of april   the company had purchased  shares at a cost of  new accounting pronouncements sfas no 
 accounting for certain financial instruments with characteristics of both liabilities and equity  which was issued may  will require redeemable preferred stock to be classified  in certain circumstances  as a liability  upon adoption by a public company at the beginning of the first interim period beginning after june  sfas no 
provides that mandatorily redeemable preferred stock should be classified as a liability if it embodies an unconditional obligation requiring the issuer to redeem the shares by transferring its assets at a specified or determinable date or upon an event certain to occur 
the company does not currently have any financial instruments with these characteristics 
sfas no 
had no effect on the company s results of operations and financial position 
in may  the fasb issued fas no 
 amendment of statement on derivative instruments and hedging activities fas 
fas amends and clarifies accounting for derivative instruments  including certain derivative instruments embedded in other contracts  and for hedging activities under fas no 
fas is effective for contracts entered into or modified after june   and for hedging relationships designated after june  the adoption of fas did not have any impact on the company s financial position or results of operations 
in december  the fasb issued sfas no 
 accounting for stock based compensation transition and disclosure 
this statement amends sfas no 
 accounting for stock based compensation  to provide alternative methods of transition for an entity that changes to the fair value method of accounting for stock based employee compensation 
in addition  sfas amends the disclosure provisions of sfas to require expanded and more prominent disclosures in annual financial statements about the method of accounting for stock based compensation and the proforma effect on reported results of applying the fair value method for 
table of contents entities that use the intrinsic value method 
the proforma disclosures are also required to be displayed prominently in interim financial statements 
the company does not intend to change to the fair value method of accounting and has included the disclosure requirements of sfas in the accompanying financial statements 
in january  the fasb issued fasb interpretation fin  consolidation of variable interest entities which was revised in december fin clarifies the application of accounting research bulletin  consolidated financial statements  for certain entities that do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties or in which equity investors do not have the characteristics of a controlling financial interest variable interest entities 
variable interest entities within the scope of fin will be required to be consolidated by their primary beneficiary 
the primary beneficiary of a variable interest entity is determined to be the party that absorbs a majority of the entity s expected losses  receives a majority of its expected returns  or both 
entities that have interests in variable interest entities or special purpose entities  fin applies for periods ending after december  application of this interpretation for all other public entities other than small business issuers is effective for periods ending after march  the adoption of fin had no impact upon the financial condition or results of operations of the company 
revenue recognition revenue is recognized for product sales upon shipment and passing of risk to the customer and when estimates of discounts  rebates  promotional adjustments  price adjustments  returns  chargebacks  and other potential adjustments are reasonably determinable  collection is reasonably assured and the company has no further performance obligations 
these estimates are presented in the financial statements as reductions to net revenues and accounts receivable 
estimated sales returns  allowances and discounts are provided for 
contract research income is recognized as work is completed and billable costs are incurred 
in certain cases  contract research income is based on attainment of designated milestones 
returns consistent with industry practice  the company maintains a return policy that allows its customers to return product within a specified period 
the company s estimate for returns is based upon its historical experience with actual returns 
while such experience has allowed for reasonable estimations in the past  history may not always be an accurate indicator of future returns 
the company continually monitors its estimates for returns and makes adjustments when it believes that actual product returns may differ from the established accruals 
chargebacks the company markets products directly to wholesalers  distributors  retail pharmacy chains  mail order pharmacies and group purchasing organizations 
the company also markets products indirectly to independent pharmacies  managed care organizations  hospitals  nursing homes and pharmacy benefit management companies  collectively referred to as indirect customers 
the company enters into agreements with its indirect customers and enters into agreements with its wholesalers to establish contract pricing for certain products 
indirect customers then independently select a wholesaler from which to actually purchase the products at these contracted prices 
the company will provide credit to the wholesaler for any difference between the contracted price and the wholesaler s invoice price 
such credit is called a chargeback 
the estimate for chargebacks is based on expected and historical sell through levels by its wholesaler customers to contracted customers 
the company continually monitors its provision for chargebacks and makes adjustments when it believes that actual chargebacks may differ from established estimates 

table of contents contractual obligations and off balance sheet arrangements the company has entered into agreements for two studies on a product hi tech has under current development 
the total commitment under the agreements is million which is expected to be paid by april  as part of our ongoing business  we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships which would have been established for the purpose of facilitating off balance sheet arrangements or other contractually narrow or limited purposes 
as of april  we are not involved in any material unconsolidated transactions 
item a 
quantitative and qualitative disclosures about market risk the company s existing credit facility bears interest at a rate selected by the company equal to the prime rate or libor plus 
this facility is exposed to market rate fluctuations and may impact the interest paid on any borrowings under the credit facility 
currently  the company has no borrowings under this facility  however  an increase in interest rates would impact interest expense on future borrowings 
the company invests in us treasury notes  government asset backed securities and corporate bonds  all of which are exposed to interest rate fluctuations 
the interest earned on these investments may vary based on fluctuations in the interest rate 
in june  the company acquired rights to market and distribute naprelan naproxen sodium controlled release tablets in the united states  its territories  and puerto rico  from elan pharmaceuticals  inc elan  a company based in ireland 
elan had provided the underlying rights to stat trade  inc sti and sti simultaneously assigned its rights to the license to hi tech 
future purchases of the product from elan are locked in at a predetermined price in us dollars and are not subject to fluctuations in foreign currency exchange rates for a period of five years 

table of contents 
